Insulin and Glucagon: Partners for Life

Area of Science:

• Endocrinology and Metabolism
• Diabetes Research
• Hormone Signaling

Background:

• Glucagon plays a critical role in glucose homeostasis and its dysregulation is central to diabetes pathogenesis.
• Targeting the glucagon pathway is a promising strategy for diabetes treatment, but its efficacy is debated.
• Previous research highlighted the complex interplay between insulin and glucagon in metabolic control.

Purpose of the Study:

• To summarize the consensus reached at the European Association for the Study of Diabetes Hagedorn Workshop regarding glucagon antagonism in diabetes.
• To elucidate the necessity of basal insulin for the therapeutic benefit of glucagon blockade.
• To review experimental findings supporting the role of insulin in glucagon receptor antagonism.

Main Methods:

• Discussion and consensus-building among leaders in glucagon biology at a workshop.
• Review of experimental data from glucagon receptor-deficient mice.
• Studies involving streptozotocin-induced and diphtheria toxin-induced pancreatic beta cell ablation in mice.

Main Results:

• A consensus was reached emphasizing the critical need for basal insulin to enable glucagon blockade's therapeutic effects.
• Studies using glucagon receptor-deficient mice with beta cell loss demonstrated key insights into this interaction.
• Experimental evidence supports that glucagon antagonism is most effective when adequate basal insulin is present.

Conclusions:

• Agents antagonizing glucagon offer significant potential for managing diabetes.
• Therapeutic efficacy of glucagon blockade is contingent upon maintaining sufficient basal insulin levels.
• Future diabetes therapies targeting glucagon must consider the essential role of basal insulin.